Get the Stockscreener App
9.51
2.36%
-0.23
After Hours:
9.51
Urogen Pharma Ltd stock is traded at $9.51, with a volume of 406.78K.
It is down -2.36% in the last 24 hours and down -7.13% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$9.74
Open:
$9.77
24h Volume:
406.78K
Relative Volume:
1.09
Market Cap:
$401.32M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.5913
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-9.94%
1M Performance:
-7.13%
6M Performance:
-32.84%
1Y Performance:
-44.35%
1-Day Range:
$9.29
$9.81
1-Week Range:
$9.29
$11.09
52-Week Range:
$9.29
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
9.51 | 401.32M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance
UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace
Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Plots Expansion, Brings In A New Asset - News & Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com
UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha
UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com India
UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio - Marketscreener.com
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Yahoo Finance
Where are the Opportunities in (URGN) - Stock Traders Daily
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
UroGen Announces Results from Subgroup Analyses of the Pivotal E - WICZ
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire
D. Boral Capital Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - MarketBeat
UroGen Pharma Ltd. Announces Results from A Long-Term Follow-Up Study with JELMYTO for Primary Treatment of Low-Grade, Upper Tract Urothelial Cancer in Adult Patients - Marketscreener.com
JELMYTO shows long-term effectiveness in cancer study By Investing.com - Investing.com Canada
JELMYTO shows long-term effectiveness in cancer study - Investing.com India
Data From A Long-Term Follow-Up Study To The Olympus Trial Published In The Journal Of Urology - Marketscreener.com
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations - StockTitan
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - Simply Wall St
Urogen Pharma's general counsel sells $82,202 in shares - MSN
(URGN) Trading Advice - Stock Traders Daily
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells 7,379 Shares of Stock - MarketBeat
SG Americas Securities LLC Has $216,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares - MarketBeat
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in Stock - Armenian Reporter
UroGen Pharma's chief medical officer sells shares worth $50,698 - MSN
UroGen Pharma's chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Canada
UroGen Pharma’s chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Nigeria
Urogen Pharma's general counsel sells $82,202 in shares By Investing.com - Investing.com South Africa
URGN (UroGen Pharma) Revenue per Share : $2.39 (TTM As of Sep. 2024) - GuruFocus.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
URGN (UroGen Pharma) EPS without NRI : $-2.60 (TTM As of Sep. 2024) - GuruFocus.com
UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian
JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):